The design of drugs for HIV and HCV

Nature Reviews Drug Discovery

Volumn 6, Issue 12, 2007, Pages 1001-1018

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; AMDOXOVIR; ANTIVIRUS AGENT; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR4 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYCLOPHILIN INHIBITOR; DAPIVIRINE; DELAVIRDINE; ELVUCITABINE; ENZYME INHIBITOR; ETRAVIRINE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; NUCLEOSIDE ANALOG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; RNA REPLICASE INHIBITOR; SERINE PROTEINASE INHIBITOR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG DESIGN; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS;

EID: 36749073433     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2424     Document Type: Review

References (161)

1. Mitsuya, H. et al. 3′-Azido-3′-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl Acad. Sci. USA 82, 7096-7100 (1985).
2. Coffin, J. et al. What to call the AIDS virus? Nature 321 10 (1986).
3. Popovic, M. et al. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science 219, 856-859 (1983).
4. Barré-Sinoussi, F. et al. Isolation ofa T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871 (1983).
5. Chermann, J. C. et al. Isolation ofa new retrovirus in a patient at risk for acquired immunodeficiency syndrome. Antibiot. Chemother. 32, 48-53 (1983).
6. De Clercq, E. Anti-HIV drugs. Verh. K. Acad. Geneesk. Belg. 64 81-104 (2007).
7. Fried, M. W. et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975-982 (2002).
8. Janssen, P. A. J. et al. In search ofa novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2, 6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 48, 1901-1909 (2005).
9. Tantillo, C. et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. 243, 369-387 (1994).
10. Pauwels R. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr. Opin. Pharmacol. 4, 437-446 (2004).
11. De Clercq, E. Strategies in the design of antiviral drugs. Nature Rev. Drug Discov. 1, 13-25 (2002).
12. De Clercq, E. & Holý, A. Acyclic nucleoside phosphonates: A key class of antiviral drugs. Nature Rev. Drug Discov. 4, 928-940 (2005).
13. De Clercq, E. Emerging anti-HIV drugs. Expert Opin. Emerging Drugs 10, 241-274 (2005).
14. Hurwitz, S. J., Otto, M. J. & Schinazi, R. F. Comparative pharmacokinetics of Racivir, (±)-β-2′, 3′-dideoxy-5-fluoro-3′-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Antiviral Chem. Chemother. 16, 117-127 (2005).
15. Herzmann, C. etal. Safety, pharmacokinetics, and efficacy of (±)-β-2′, 3′-dideoxy-5-fluoro-3′-thiacytidine with efavirenz and stavudine in antiretroviral-naïve human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 49, 2828-2833 (2005).
16. Cahn, P. et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 20, 1261-1268 (2006).
17. Frankel, F. A., Coutsinos, D., Xu, H. & Wainberg, M. A. Kinetics of inhibition of HIV type 1 reverse transcriptase-bearing NRT1-associated mutations by apricitabine triphosphate. Antiviral Chem. Chemother. 18, 93-101 (2007).
18. Wainberg, M. A., Cahn, P., Bethell, R. C., Sawyer, J. & Cox, S. Apricitabine: A novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection. Antiviral Chem. Chemother. 18, 61-70 (2007).
19. Bethell, R. et al. Evaluation of in vitro interactions between apricitabine and other deoxycytidine analogues. Antimicrob. Agents Chemother. 21 May 2007 (doi:10.1128/AAC.01204-06).
20. Holdich, T., Shiveley, L. A. & Sawyer, J. Effect of lamivudine on the plasma and intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob. Agents Chemother. 51, 2943-2947 (2007).
21. Thompson, M. A. et al. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 19, 1607-1615 (2005).
22. Gripshover, B. M. et al. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV- 1 -infected subjects failing current therapy (AACTG A5118). Antiviral Ther. 11, 619-623 (2006).
23. Narayanasamy, J. et al. Synthesis and anti-HIV activity of (-)β-D-(2R, 4R)- 1, 3-dioxolane-2, 6-diamino purine (DAPD) (amdoxovir) and (-)-β-D-(2R, 4R)-1, 3-dioxolane guanosine (DXG) prodrugs. Antiviral Res. 75, 198-209 (2007).
24. Ghosn, J. et al. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: Results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial. HIV Med. 8 142-147 (2007).
25. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chemistry & Biodiversity 1, 44-64 (2004).
26. Hang, J. O. et al. Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). Biochem. Biophys. Res. Commun. 352, 341-350 (2007).
27. Goebel, F. et al. Short-term antiviral activity of TMC278: A novel NNRTI in treatment-naive HIV-1-infected subjects. AIDS 20, 1721-1726 (2006).
28. The TMC125-C223 Writing Group. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: Primary 24-week analysis. AIDS 21, F1-F10 (2007).
29. Boffito, M. et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 21, 1449-1455 (2007).
30. Vingerhoets, J. et al. TMC 125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J. Virol. 79, 12773-12782 (2005).
31. Jespers, V. A. et al. Dose-ranging phase 1 study of TMC 120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J. Acquir. Immune Defic. Syndr. 44, 154-158 (2007).
32. Malcolm, R. K., Woolfson, A. D., Toner, C. F., Morrow, R. J. & McCullagh, S. D. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J. Antimicrob. Chemother. 56, 954-956 (2005).
33. Woolfson, A. D., Malcolm, R. K., Morrow, R. J., Toner, C. F. & McCullagh, S. D. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm. 325, 82-89 (2006).
34. De Francesco, R. & Migliaccio, G. Challenges and successes in developing new therapies for hepatitis C. Nature 436, 953-960 (2005).
35. Carroll, S. S. et al. Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. J. Biol. Chem. 278, 11979-11984 (2003).
36. Tomassini, J. E. et al. Inhibitory effect of 2′-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrob. Agents Chemother. 49 2050-2058 (2005).
37. Migliaccio, G. et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278, 49164-49170 (2003).
38. Eldrup, A. B. et al. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 47, 2283-2295 (2004).
39. Olsen, D. B. et al. A 7-deaza-adeosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48 3944-3953 (2004).
40. Carroll, S. et al. Nucleoside inhibitors of hepatitis C virus RNA polymerase: Improved potency and liver targeting with 7-deaza-7-fluoro-2′-C-methyladenosine. Late Breakars, Twentieth International Conference on Antiviral Research, Palm Springs, California, USA 2007, LB-01.
41. Stuyver, L. J. et al. Inhibition of hepatitis C replicon RNA synthesis by β-D-2′-deoxy-2′-fluoro-2′-C-methylcy tidine: A specific inhibitor of hepatitis C virus replication. Antiviral Chem. Chemother. 17, 79-87 (2006).
42. Klumpp, K. et al. The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281, 3793-3799 (2006).
43. Klumpp, K. et al. Design and characterization of R1626, a prodrug of the HCV replication inhibitor R1479 (4′-azidocytidine) with enhanced oral bioavailability. Antiviral Res. 74, A35, abstract 21 (2007).
44. Smith, D. et al. Novel 4′-azido-2′-deoxy-nucleoside analogs are potent inhibitors of NS5B-dependent HCV replication. Antiviral Res. 74, A36, abstract 22 (2007).
45. Afdhal, N. et al. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: Antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 726A (2004).
46. Coelmont, L. et al. Ribavirin antagonizes the in vitro anti-hepatitis C virus activity of 2′-C-methylcytidine, the active component of valopicitabine. Antimicrob. Agents Chemother. 50 3444-3446 (2006).
47. Le Pogam, S. et al. In vitro selected Con 1 subgenomic replicons resistant to 2′C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351, 349-359 (2006).
48. Summa, V. et al. Discovery of α, γ-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. J. Med. Chem. 47, 14-17 (2004).
49. Summa, V. et al. HCV NS5b RNA-dependent RNA polymerase inhibitors: from α, γ-diketoacids to 4, 5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids Design and synthesis. J. Med. Chem. 47, 5336-5339 (2004).
50. Beaulieu, P. L. et al. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: Discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorg. Med. Chem. Lett. 14, 967-971 (2004).
51. Di Marco, S. et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J. Biol. Chem. 280, 29765-29770 (2005).
52. Harper, S. et al. Development and preliminary optimization of indole-N-actamide inhibitors of hepatitis C virus NS5B polymerase. J. Med. Chem. 48, 1314-1317 (2005).
53. Dhanak, D. et al. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277, 38322-38327 (2002).
54. Tomei, L. et al. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78, 938-846 (2004).
55. Wang, M. et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278, 9489-9495 (2003).
56. Chan, L. et al. Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. Bioorg. Med. Chem. Lett. 14 793-796 (2004).
57. Biswal, B. K. et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. 280, 18202-18210 (2005).
58. Howe, A. Y. et al. Novel nonnucleoside inhibitor of hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 48, 4813-4821 (2004).
59. Zhou, Y. et al. Potent HCV NS5B polymerase inhibitors derived from 5-hydroxy-3(2H)-pyridazinones: Part I. Exploration of pyridazinone 4-substituent variation. Antiviral Res. 74, A38, abstract 27 (2007).
60. Zhou, Y. et al. Potent HCV NS5B polymerase inhibitors derived from 5-hydroxy-3(2H)-pyridazinones: Part 2. Variation of the 2- and 6-pyridazinone substituents. Antiviral Res. 74, A51-A52, abstract 59 (2007).
61. Gopalsamy, A. et al. Design and synthesis of 3, 4-dihydro-1H-[1]-benzothieno[2, 3-c]pyran and 3, 4-dihydro-1H-pyrano[3, 4-b]benzofuran derivatives as non-nucleoside inhibitors of HCV NS5B RNA dependent RNA polymerase. Bioorg. Med. Chem. Lett. 16, 457-460 (2006).
62. Love, R. A. et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77, 7575-7581 (2003).
63. Tomei, L., Altamura, S., Paonessa, G., De Francesco, R., Migliaccio, G. HCV antiviral resistance: The impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase. Antiviral Chem. Chemother. 16, 225-245 (2005).
64. Baginski, S. G. et al. Mechanism of action of a pestivirus antiviral compound. Proc. Natl Acad. Sci. USA 97, 7981-7986 (2000).
65. Paeshuyse, J. et al. A novel, highly selective inhibitor of pestivirus replication that targets the viral RNA-dependent RNA polymerase. J. Virol. 80, 149-160 (2006).
66. Pürstinger, G., Paeshuyse, J., De Clercq, E. & Neyts, J. Antiviral 2, 5-disubstituted imidazo-[4, 5-c]pyridines: From anti-pestivirus to anti-hepatitis C virus activity. Bioorg. Med. Chem. Lett. 17 390-393 (2007).
67. Vliegen, I. et al. Substituted imidazopyridines as potent inhibitors of hepatitis C virus replication that target the viral polymerase. Antiviral Res. 74, A37, abstract 26 (2007).
68. Cahn, P. et al. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin. Infect. Dis. 43, 1347-1356 (2006).
69. Gathe, J. et al. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial. Clin. Infect. Dis. 43, 1337-1346 (2006).
70. Lalezari, J. P., Ward, D. J., Tomkins, S. A. & Garges, H. P. Preliminary safety and efficacy data of brecanavir, a novel HIV-1 protease inhibitor: 24 week data from study HPR10006. J. Antimicrob. Chemother. 60, 170-174 (2007).
71. Ford, S. L. et al. Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother. 50, 2201-2206 (2006).
72. Reddy Y. S. et al. Safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus type 1 protease inhibitor, following repeat administration with and without ritonavir in healthy adult subjects. Antimicrob. Agents Chemother. 51, 1202-1208 (2007).
73. Brecanavir's hopes dashed. AIDS Patients Care STDs 21, 143 (2007).
74. Lamarre, D. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus, Nature 426 186-189 (2003).
75. Lin, C. et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 279, 17508-17514 (2004).
76. Venkatraman, S. et al. Discovery of (IR, 5S)-N-[3-amino-1-(cyclobutylmethyl)-2, 3-dioxopropyl]-3-[2(S)- [[[(1, 1-dimethylethyl)amino]carbonyl]-amino]-3, 3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-aza-bicyclo[3.1.0] hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 49, 6074-6086 (2006).
77. Malcolm, B. A. et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob. Agents Chemother. 50, 1013-1020 (2006).
78. Prongay, A. J. et al. Discovery of the HCV NS3/4A protease inhibitor [1R, 5S)-N-[3-amino-1-(cyclobutylmethyl)-2, 3-dioxopropyl]-3-[2(S)-[[[(1, 1-di methylethyl)amino] carbonyl]-amino]-3, 3-dimethyl-1-oxobutyl]-6, 6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J. Med. Chem. 50, 2310-2318 (2007).
79. Yi, M. et al. Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. J. Biol. Chem. 281 8205-8215 (2006).
80. Bogen, S. L. et al. Discovery of SCH44621 1 (SCH6): A new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. J. Med. Chem. 49, 2750-2757 (2006).
81. Hinrichsen, H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347-1355 (2004).
82. Thibeault, D. et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 78, 7352-7359 (2004).
83. Tong, X. et al. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 45, 1353-1361 (2006).
84. Perni, R. B. et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50, 899-909 (2006).
85. Lin, K., Perni, R. B., Kwong, A. D. & Lin, C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob. Agents Chemother. 50, 1813-1822 (2006).
86. Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007).
87. Lin, C. et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 280, 36784-36791 (2005).
88. Zhou, Y. et al. Phenotypic and structural analyses of HCV NS3 protease ARG 155 variants: Sensitivity to telaprevir (VX-950) and interferon alpha. J. Biol. Chem. 6 June 2007 (doi:10.1074/ jbc.M610207200).
89. Courcambeck, J. et al. Resistance of hepatitis C virus to NS3-4A protease inhibitors: Mechanisms of drug resistance induced by R155O, A156T, D168A and D168V mutations. Antivirol Ther. 11, 847-855 (2006).
90. Matthews, T. et al. Enfuvirtide: The first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nature Rev. Drug Discov. 3, 215-225 (2004).
91. Westby, M. & van der Ryst, E. CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection. Antiviral Chem. Chemother. 16, 339-354 (2005).
92. Moradpour, D., Perin, F. & Rice, C. M. Replication of hepatitis C virus. Nature Rev. Microbiol. 5, 453-463, 2007
93. Myers, S. A. et al. A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antiviral Ther. 11, 935-939 (2006).
94. Molto, J. et al. Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. Antiviral Ther. 11, 47-51 (2006).
95. Raffi, F et al. Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirticle in the T-20 versus Optimized Regimen Only (TORO) trials. Clin. Infect Dis. 42, 870-877 (2006).
96. Lu, J. et al. Rapid emergence of enfuvirtide resistance in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. 43, 60-64 (2006).
97. Labrosse, B. et al. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J. Virol. 80, 8807-8819 (2006).
98. Ray, N. et al. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J. Virol. 81. 3240-3250 (2007).
99. Heredia, A. et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: An approach to suppress R5 strains of HIV-1. Proc. Natl Acad. Sci. US4 100, 10411-10416 (2003).
100. Heredia, A. et al. Rapamycin reduces CCR5 density levels on CD4 T cells and this effect results in potentiation of Enfuvirticle (T-20) against R5 strains of HIV-1 in vitro. Antimicrob. Agents Chemother. 51, 2489-2496 (2007).
101. De Clercq, E. The bicyclam AMD3100 story. Nature Rev. Drug Discovery 2, 581-587 (2003).
102. Darr, P. et al. Maraviroc (UK-427857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
103. Fätkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, inpatients infected with HIV-1. Nature Med. 11, 1170-1172 (2005).
104. Westby, M. et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80, 4909-4920 (2006).
105. Westby, M. et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81, 2359-2371 (2007).
106. Strizki, J. M. et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 49 4911-4919 (2005).
107. Schürmann, D. et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-inficted adults. AIDS 21, 1293-1299 (2007).
108. Gulick, R. M. et al. Phase 2 Study of the safety and efficacy of Vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J. Infect. Dis. 196 304-312 (2007).
109. Pugach, P. et al. HIV- 1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361, 212-228 (2007).
110. Wilkin, T. J. et al. HIV type 1 chemokine co-receptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin. Infect. Dis. 44, 591-595 (2007).
111. Murga, J. D., Franti, M., Pevear, D. C., Maddon, P. J. & Olson, W. C. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 50, 3289-3296 (2006).
112. A C. et al. CCR5 Small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Mol. Phormocol. 72, 18-28 (2007).
113. Sato, M. et al. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 49, 1506-1508 (2006).
114. Daelemans, D., Lu, R., De Clercq, E. & Engelman, A. Characterization of a replication-competent, integrase-defective human immunodeficiency virus (HIV/simian virus 40 chimera as a powerful tool for the discovery and validation of HIV integrase inhibitors. J. Virol. 81, 4381-4385 (2007).
115. Markowitz, M. et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43, 509-515 (2006).
116. Markowitz, M. et al. Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part of combination ART in treatment-naïve HIV-1-infected patients. XVI International AIDS Conference, Toronto, Canada 2006. Abstract THLB0214.
117. Grinsztejn, B. et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 369, 1261-1269 (2007).
118. DeJesus, E. et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J. Acquir. Immune Defic. Syndr. 43, 1-5 (2006).
119. Ramanathan, S., Shen, G., Cheng, A. & Kearney, B. P. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofavir disoproxil fumarate and ritonavir-boosted GS-9137. J. Acquir Immune Defic. Syndr 45, 274-279 (2007).
120. Zolopa, A. R. et al. The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients. Oral presentations from the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA, 2007, 143 LB.
121. Li, F. et al. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl Acad. Sci. USA 100, 13555-13560 (2003).
122. Adamson, C. S. et al. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). J. Virol. 80, 10957-10971 (2006).
123. Martin, D. E., Blum, R., Doto, J., Galbraith, H. & Ballow, C. Multipie-Dose Pharmacokinetics and safety of bevirimat, a novel inhibitor of HIV maturation, in healthy volunteers. Clin. Pharmacokinet. 46. 589-598 (2007).
124. Martin. D. E. et al. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob. Agents Chemother. 51, 3063-3066 (2007).
125. Wen, Z., Martin, D. E., Bullock, P., Lee, K.-H. & Smith, P. C. Glucuronidation of anti-HIV drug candidate bevirimat: Identification of human UDP-glucuronosyltransferases and species differences. Drug Metab. Dispos. 35, 440-448 (2007).
126. Rosenwirth, B. et al. Inhibition of human immunodeficiency virus type 1 replication by SDZ NIM 811, a nonimmunosuppressive cyclosporine analog. Antimicrob. Agents Chemother. 38, 1763-1772 (1994).
127. Luban, J., Bossolt, K. L., Franke, E. K., Kalpana, G. V. & Goff, S. P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73, 1067-1078 (1993).
128. Watashi, K. et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol. Cell 19, 111-122 (2005).
129. Tan, S. L., Pause, A., Shi, Y. & Sonenbere, N. Hepatitis C therapeutics: current status and emerging strategies. Nature Rev. Drug Discov. 1, 867-881 (2002).
130. Rice, C. M. & You, S. Treating hepatitis C: Can you teach old dogs new tricks? Hepatology 42, 1455-1458 (2005).
131. Paeshuyse, J. et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43, 761-770 (2006).
132. Coelmont, L. et al. The cyclophilin inhibitor Debio-025 is a potent inhibitor of hepatitis C virus replication in vitro with a unique resistance profile. Antiviral Res. 74, A39, abstract 29 (2007).
133. McHutchison, J. G. et al. A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. J. Hepatol. 44, 88-96 (2006).
134. Krönke, J. et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J. Virol. 78, 3436-3446 (2004).
135. Johnston, B. et al. shRNAs targeting hepatitis C: Effects of sequence and structural features, and comparison with siRNA. Antiviral Res. 74, A59, abstract 79 (2007).
136. Pavlovic, D. et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc. Natl Acad. Sci. USA 100, 6104-6108 (2003).
137. Chapel, C. et al. Antiviral effect of α-glucosidase inhibitors on viral morphogenesis and binding properties of hepatitis C virus-like particles. J. Gen. Virol. 87, 861-871 (2006).
138. Hwang, D.-R. et al. Inhibition of hepatitis C virus replication by arsenic trioxide. Antimicrob. Agents Chemother. 48, 2876-2882 (2004).
139. Hatano, H. & Deeks, S. G. Drug resistant HIV. Promising research on three new drugs gives hope for chronically infected patients. Br. Med. J. 334, 1124-1125 (2007).
140. Stephenson, J. Researchers buoyed by novel HIV drugs will expand drug arsenal against resistant virus. JAMA 297, 1535-1536 (2007).
141. Josephson, F. et al. Antiretroviral treatment of HIV infection: Swedish recommendations 2007. Scand. J. Infect. Dis. 39, 486-507 (2007).
142. Ren, J. et al. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu 1001le, Lys 101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J. Med. Chem. 50, 2301-2309 (2007).
143. Herschhorn, A. et al. De novo parallel design. synthesis and evaluation of inhibitors against the reverse transcriptase of human immunodeficiency virus type-1 and drug-resistant variants. J. Med. Chem. 50, 2370-2384 (2007).
144. Gonzalez de Requena, D. et al. Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. AIDS 20, 1977-1979 (2006).
145. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N. Engl. J. Med. 356, 1723-1735 (2007).
146. MacArthur, R. D. et al. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): A long-term randomised trial. Lancet 368, 2125-2135.
147. Tomei, L. et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77, 13225-13231 (2003).
148. Le Pogam, S. et al. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80 6146-6154 (2006).
149. Mo, H. et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob. Agents Chemother. 49, 4305-4314 (2005).
150. Pauwels, R. Aspects of successful drug discovery and development. Antiviral Res. 71, 77-89 (2006).
151. Chen, J. C.-H. et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding. Proc. Natl Acad. Sci. USA 97, 8233-8238 (2000).
152. Jones, G. et al. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, USA, poster 627.
153. De Clercq, E. From adefovir to AtriplaTM via tenofovir, VireadTM and TruvadaTM. Future Virol. 1, 709-715 (2006).
154. Gallant, J. E. et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. 354, 251-260 (2006).
155. Pozniak, A. L. et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naīve patients. J. Aquir. Immune Defic. Syndr. 43, 535-540 (2006).
156. Hoofnagle, J. H. & Seeff, L. B. Peginterferon and ribavirin for chronic hepatitis C. N. Engl. J. Med. 355, 2444-2451 (2006).
157. Potter, C. W, Phair, J. P., Vodinelich, L., Fenton, R. & Jennings, R. Antiviral, immunosuppressive and antitumour effects of ribavirin. Nature 259, 496-497 (1976).
158. Streeter, D. G. et al. Mechanism of action of 1-β-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl Acad. Sci. USA 70 1174-1178 (1973).
159. Leyssen, P., De Clercq, E. & Neyts, J. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication. Mol. Pharmacol. 69, 1461-1467 (2006).
160. De Clercq, E. Antiviral agents active against influenza A viruses. Nature Rev. Drug Discov. 5, 1015-1025 (2006).
161. De Clercq, E. AIDS in the third world: How to stop the HIV infection? Verh. K. Acad. Geneesk. Belg. 64, 65-80 (2007).